{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:23:33Z","timestamp":1791149013008,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T00:00:00Z","timestamp":1417132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s12032-014-0335-7","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T14:20:31Z","timestamp":1417443631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study"],"prefix":"10.1007","volume":"32","author":[{"given":"Carmen","family":"Fucile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Marenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bazzica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Zuccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lantieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Robbiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Di Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Stura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Picciotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,28]]},"reference":[{"key":"335_CR1","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC cancer base no. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http:\/\/globocan.iarc.fr . Accessed 23 Jan 2013."},{"key":"335_CR2","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"335_CR3","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 2006;66:11851\u20138.","journal-title":"Cancer Res"},{"key":"335_CR4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/14656566.2011.546346","volume":"12","author":"YS Guan","year":"2011","unstructured":"Guan YS, He Q. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert Opin Pharmacother. 2011;12:303\u201313.","journal-title":"Expert Opin Pharmacother"},{"key":"335_CR5","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s10637-011-9764-8","volume":"30","author":"J Arrondeau","year":"2012","unstructured":"Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30:2046\u20139.","journal-title":"Invest New Drugs"},{"key":"335_CR6","unstructured":"European Medicines Agency. Sorafenib summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000690\/WC500027704.pdf . Accessed 23 Jan 2013."},{"key":"335_CR7","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s10637-011-9760-z","volume":"30","author":"M Hornecker","year":"2012","unstructured":"Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, Taieb F, et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs. 2012;30:1991\u20132000.","journal-title":"Invest New Drugs"},{"key":"335_CR8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP Erp Van","year":"2009","unstructured":"Van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692\u2013706.","journal-title":"Cancer Treat Rev"},{"key":"335_CR9","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12:7271\u20138.","journal-title":"Clin Cancer Res"},{"key":"335_CR10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426\u201337.","journal-title":"Oncologist"},{"key":"335_CR11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965\u201372.","journal-title":"J Clin Oncol"},{"key":"335_CR12","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1349-7006.2008.00837.x","volume":"99","author":"H Minami","year":"2008","unstructured":"Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 2008;99:1492\u20138.","journal-title":"Cancer Sci"},{"key":"335_CR13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00280-010-1474-y","volume":"68","author":"WJ Heinz","year":"2011","unstructured":"Heinz WJ, Kahle K, Helle-Beyersdorf A, Schirmer D, Lenker U, Keller D, et al. High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemother Pharmacol. 2011;68:239\u201345.","journal-title":"Cancer Chemother Pharmacol"},{"key":"335_CR14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2125.2011.03963.x","volume":"72","author":"L Jain","year":"2011","unstructured":"Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol. 2011;72:294\u2013305.","journal-title":"Br J Clin Pharmacol"},{"key":"335_CR15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","volume":"50","author":"P Gion Di","year":"2011","unstructured":"Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011;50:551\u2013603.","journal-title":"Clin Pharmacokinet"},{"key":"335_CR16","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1634\/theoncologist.2011-0439","volume":"17","author":"P Boudou-Rouquette","year":"2012","unstructured":"Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M, et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic\/pharmacodynamic analysis. Oncologist. 2012;17:1204\u201312.","journal-title":"Oncologist"},{"key":"335_CR17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.critrevonc.2010.03.006","volume":"78","author":"J Bellmunt","year":"2011","unstructured":"Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011;78:24\u201332.","journal-title":"Crit Rev Oncol Hematol"},{"key":"335_CR18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020\u20132.","journal-title":"Hepatology"},{"key":"335_CR19","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jpba.2009.02.008","volume":"49","author":"B Blanchet","year":"2009","unstructured":"Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49:1109\u201314.","journal-title":"J Pharm Biomed Anal"},{"key":"335_CR20","unstructured":"ICH. Harmonised tripartite guidelines: validation of analytical procedures: methodology 6 November 1996. FDA Federation Reg. 1997; 62:25634\u201315635."},{"key":"335_CR21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","volume":"69","author":"GM Keating","year":"2009","unstructured":"Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69:223\u201340.","journal-title":"Drugs"},{"key":"335_CR22","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","volume":"11","author":"JW Clark","year":"2005","unstructured":"Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11:5472\u201380.","journal-title":"Clin Cancer Res"},{"key":"335_CR23","first-page":"40","volume":"4","author":"GK Abou-Alfa","year":"2011","unstructured":"Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child\u2013Pugh A versus B cirrhosis. Gastrointest Cancer Res. 2011;4:40\u20134.","journal-title":"Gastrointest Cancer Res"},{"key":"335_CR24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1535-7163.MCT-09-0663","volume":"9","author":"JS Lagas","year":"2010","unstructured":"Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010;9:319\u201326.","journal-title":"Mol Cancer Ther"},{"key":"335_CR25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","volume":"4","author":"H Burger","year":"2005","unstructured":"Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005;4:747\u201352.","journal-title":"Cancer Biol Ther"},{"key":"335_CR26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1346-8138.2010.01059.x","volume":"38","author":"M Lijima","year":"2011","unstructured":"Lijima M, Fukino K, Adachi M, Tsukamoto T, Murai M, Naito S, et al. Sorafenib-associated hand-foot syndrome in Japanese patients. J Dermatol. 2011;38:261\u20136.","journal-title":"J Dermatol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-014-0335-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0335-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:31:46Z","timestamp":1559442706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-014-0335-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0335-7","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,28]]},"article-number":"335"}}